Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Fig. 7

Statistics of combination non-engineered and engineered NK cell therapies. The pie charts present the types of combination therapies under clinical evaluation, as reported on ClinicalTrials.gov until December 2021, with non-engineered NK cells (N = 62 clinical trials) and with engineered NK cells (N = 34 trials). For every pie, numbers indicate the percentage of the whole taken by each slice. A Types of combinations with non-engineered and engineered NK cells: NK cell priming agents, adoptive cell therapy, antibodies, co-stimulation, molecular inhibitors, NK cell engagers; multiple combinations indicate the use of more than one of these categories. B Breakdown of the surface tumor antigens targeted by monoclonal antibodies used in combination with engineered and non-engineered NK cells. In B, on trial can have more than one target

Back to article page